AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33229715 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing walking training (KLTP)
Number of subjects: 320
Study 33229973 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid encapsulating polymeric microparticles for longer lasting pain relief
Number of subjects: 0
Study 33229973 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically charged biomaterials for intra-cartilage targeting
Number of subjects: 0
Study 33229973 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral vectors for gene therapy
Number of subjects: 0
Study 33230035 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensation training and substitution therapies
Number of subjects: 0
Study 33230035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training inside the blind field
Number of subjects: 0
Study 33230035 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier intervention and advanced training procedures
Number of subjects: 0
Study 33230035 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive brain stimulation and pharmacological adjuvants
Number of subjects: 0
Study 33230035 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive rehabilitative strategies
Number of subjects: 0
Study 33230103 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-specific chimeric antigen receptor T cell (CD19 CAR T) therapy
Number of subjects: 51
Study 33230210 — intervention group
Group type: EXPERIMENTAL
Intervention: peposertib 100-200 mg once daily or 150-400 mg twice daily (BID) in 21-day cycles
Number of subjects: 31
Study 33230210 — intervention group
Group type: EXPERIMENTAL
Intervention: peposertib 400 mg BID (RP2D)
Number of subjects: 31
Study 33230959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 30
Study 33230961 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-weight-loss responders (HWLRs) with ≥20% total body weight loss (TBWL) at 5 years after MBS
Number of subjects: 192
Study 33230961 — intervention group
Group type: COMPARATOR
Intervention: Lower-weight-loss responders (LWLRs) with <20% total body weight loss (TBWL) at 5 years after MBS
Number of subjects: 192
Study 33230962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketosis (βHB: 1.24±0.82 mmol/L in fasting)
Number of subjects: 87
Study 33231108 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-specific win ratios
Number of subjects: 0
Study 33231108 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum test based on event-specific win ratios
Number of subjects: 0
Study 33231487 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I/ARB therapy
Number of subjects: 338
Study 33231487 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I/ARB therapy during hospitalization
Number of subjects: 338
Study 33231550 — intervention group
Group type: EXPERIMENTAL
Intervention: MoMba Live Long system (smartphone-based breath carbon monoxide meter)
Number of subjects: 10
Study 33231550 — intervention group
Group type: COMPARATOR
Intervention: Commercial monitor (piCO)
Number of subjects: 10
Study 33231556 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition (Stroop-like exercises)
Number of subjects: 90
Study 33231556 — intervention group
Group type: EXPERIMENTAL
Intervention: Updating (N-back-type exercises)
Number of subjects: 90
Study 33231556 — intervention group
Group type: COMPARATOR
Intervention: Control active (quiz game exercise)
Number of subjects: 90
Study 33231556 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition and Updating
Number of subjects: 90
Study 33231559 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 131
Study 33231709 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (HbA1c ≥6.5%)
Number of subjects: 27337
Study 33231709 — intervention group
Group type: COMPARATOR
Intervention: Group I (HbA1c <5.7%)
Number of subjects: 27337
Study 33231709 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (HbA1c 5.7-6.4%)
Number of subjects: 27337
Study 33232306 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration or optogenetic stimulation of vasopressin in the lateral septum
Number of subjects: 0
Study 33232306 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 33232348 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing techniques
Number of subjects: 15
Study 33232348 — intervention group
Group type: COMPARATOR
Intervention: Current practices in oncology (without Motivational Interviewing)
Number of subjects: 15
Study 33232473 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FVIII
Number of subjects: 0
Study 33232483 — intervention group
Group type: COMPARATOR
Intervention: PsO
Number of subjects: 104
Study 33232483 — intervention group
Group type: COMPARATOR
Intervention: PsA
Number of subjects: 104
Study 33232483 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA and PsO
Number of subjects: 104
Study 33232518 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 3738
Study 33232518 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 3738
Study 33232518 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol plus oxytocin
Number of subjects: 3738
Study 33232613 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the neurogenic bladder symptom score (NBSS)
Number of subjects: 102
Study 33234490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and Temozolomide
Number of subjects: 0
Study 33234626 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended ICF Checklist V.2.1a
Number of subjects: 65
Study 33234643 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) group
Number of subjects: 980
Study 33234643 — intervention group
Group type: COMPARATOR
Intervention: Control group (offspring of healthy mothers)
Number of subjects: 980
Study 33234651 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological tests for COVID-19 (IgM and IgG antibodies)
Number of subjects: 400
Study 33234651 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (prepandemic time)
Number of subjects: 400
Study 33234651 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of IgM and IgG antibodies
Number of subjects: 400
Study 33234651 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of false negative PCR tests
Number of subjects: 400
Study 33234656 — intervention group
Group type: EXPERIMENTAL
Intervention: Predi-COVID participants
Number of subjects: 500
Study 33234656 — intervention group
Group type: EXPERIMENTAL
Intervention: Predi-COVID-H participants
Number of subjects: 500
Study 33234662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tumour infiltrating lymphocytes (TIL) and anti-PD-1
Number of subjects: 0
Study 33234662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TIL, pegylated-interferon-alpha (PEG-IFNa) and anti-PD-1
Number of subjects: 0
Study 33234662 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy evaluation in phase II
Number of subjects: 0
Study 33234944 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated diabetes
Number of subjects: 36762
Study 33234944 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally treated diabetes
Number of subjects: 36762
Study 33234944 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary-treated diabetes
Number of subjects: 36762
Study 33234944 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 36762
Study 33235353 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived anti-CD19 CAR T cells
Number of subjects: 28
Study 33235353 — intervention group
Group type: COMPARATOR
Intervention: DLI
Number of subjects: 28
Study 33235468 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan-containing regimen
Number of subjects: 264
Study 33235468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic regimen (oxaliplatin-containing or irinotecan-containing)
Number of subjects: 264
Study 33235733 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncoxin-Viusid (OV)
Number of subjects: 25
Study 33235971 — intervention group
Group type: EXPERIMENTAL
Intervention: GLB+NGx (modified Group Lifestyle Balance with nutrigenomics)
Number of subjects: 140
Study 33235971 — intervention group
Group type: COMPARATOR
Intervention: Standard GLB (Group Lifestyle Balance)
Number of subjects: 140
Study 33235996 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic conformal radiotherapy (SCRT)
Number of subjects: 200
Study 33235996 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (ConvRT)
Number of subjects: 200
Study 33236064 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep quality (PSQI #1)
Number of subjects: 2205
Study 33236064 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep disturbances (PSQI #5)
Number of subjects: 2205
Study 33236064 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep parameters
Number of subjects: 2205
Study 33236084 — intervention group
Group type: EXPERIMENTAL
Intervention: Index offspring (mothers with T1D)
Number of subjects: 581
Study 33236084 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1
Number of subjects: 581
Study 33236084 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean mass
Number of subjects: 581
Study 33236084 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between IR and IGF-1
Number of subjects: 581
Study 33236783 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 333
Study 33236943 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax
Number of subjects: 0
Study 33237035 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS serious game module
Number of subjects: 25
Study 33237035 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training app
Number of subjects: 25
Study 33237035 — intervention group
Group type: COMPARATOR
Intervention: OSCE scores
Number of subjects: 25
Study 33237037 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Bridge (using Care Connector and ePRO)
Number of subjects: 600
Study 33237291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilblain-like lesions patients
Number of subjects: 40
Study 33237291 — intervention group
Group type: COMPARATOR
Intervention: Patients with mild-severe acute COVID-19
Number of subjects: 40
Study 33237355 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised pelvic floor muscle training (PFMT) over 12 weeks, including six physiotherapy sessions and a home PFMT program.
Number of subjects: 77
Study 33237355 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of cure identified through binary logistic regression model: ICIQ-UI-SF, PFM tone, bladder neck (BN) height in a quiet standing position, and BN height during a cough in a standing position.
Number of subjects: 77
Study 33237534 — intervention group
Group type: EXPERIMENTAL
Intervention: INL-001 implants (3 implants, each containing 100 mg bupivacaine HCl)
Number of subjects: 50
Study 33237534 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine HCl infiltration (175 mg)
Number of subjects: 50
Study 33238029 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization (THD)
Number of subjects: 10
Study 33238029 — intervention group
Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy
Number of subjects: 10
Study 33238043 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNBs)
Number of subjects: 3061
Study 33238043 — intervention group
Group type: COMPARATOR
Intervention: No nerve block (or sham block)
Number of subjects: 3061
Study 33238176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (diet and physical activity)
Number of subjects: 1148
Study 33238176 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1148
Study 33238176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions
Number of subjects: 1148
Study 33238176 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle interventions and Standard care
Number of subjects: 1148
Study 33238584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower household income
Number of subjects: 163
Study 33238584 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher household crowding
Number of subjects: 163
Study 33238584 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal secondary education
Number of subjects: 163
Study 33238584 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal higher education
Number of subjects: 163
Study 33238584 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in Bolsa Família social protection programme
Number of subjects: 163
Study 33238728 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Ready Very Brief Intervention
Number of subjects: 0
Study 33238908 — intervention group
Group type: EXPERIMENTAL
Intervention: GERO cohort intervention (multidimensional evaluation including socio-demographic, biomedical, psychosocial, neuropsychological, neuropsychiatric, and motor assessments)
Number of subjects: 300
Study 33238908 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews at months 6, 12, 24, and 30
Number of subjects: 300
Study 33238944 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluidine blue (TB)
Number of subjects: 30
Study 33238944 — intervention group
Group type: COMPARATOR
Intervention: Frozen section (FS)
Number of subjects: 30
Study 33239013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10g vital wheat gluten (low in FODMAPs) in 100ml water
Number of subjects: 295
Study 33239053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 33239053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33239056 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 46
Study 33239079 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week RSTEP HIIT program, 2-3 times per week, 10 cycles of 60-s intervals at 90% VO
Number of subjects: 15
Study 33239124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask use adherence
Number of subjects: 152
Study 33239124 — intervention group
Group type: EXPERIMENTAL
Intervention: Absenteeism due to influenza symptoms
Number of subjects: 152
Study 33239124 — intervention group
Group type: EXPERIMENTAL
Intervention: Presenteeism with respiratory symptoms
Number of subjects: 152
Study 33239124 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza symptom reporting
Number of subjects: 152
Study 33239124 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza virus shedding
Number of subjects: 152
Study 33239226 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-dose Havrix vaccine
Number of subjects: 600
Study 33239226 — intervention group
Group type: COMPARATOR
Intervention: 2-dose Havrix vaccine
Number of subjects: 600
Study 33239228 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine (3 doses on Day 1, Month 2, Month 6)
Number of subjects: 766
Study 33239386 — intervention group
Group type: EXPERIMENTAL
Intervention: GD2-directed CAR-T cells
Number of subjects: 12
Study 33239386 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparative lymphodepletion
Number of subjects: 12
Study 33239393 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell transcriptomics from dissociated kidneys
Number of subjects: 0
Study 33239407 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic Risk Score (PRS)
Number of subjects: 0
Study 33239407 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history
Number of subjects: 0
Study 33239407 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history and PRS combined
Number of subjects: 0
Study 33239440 — intervention group
Group type: COMPARATOR
Intervention: miR-34a-5p
Number of subjects: 22
Study 33239440 — intervention group
Group type: COMPARATOR
Intervention: miR-345-5p
Number of subjects: 22
Study 33239440 — intervention group
Group type: COMPARATOR
Intervention: miR-200c-3p
Number of subjects: 22
Study 33239440 — intervention group
Group type: COMPARATOR
Intervention: miR-10a-3p
Number of subjects: 22
Study 33239737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 33239737 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 0
Study 33239737 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS ≥ 50
Number of subjects: 0
Study 33239737 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS
Number of subjects: 0
Study 33239818 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-measured sedentary behavior (SB) duration
Number of subjects: 144
Study 33239818 — intervention group
Group type: EXPERIMENTAL
Intervention: Different intensities of physical activity (PA)
Number of subjects: 144
Study 33239899 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance defined by Homeostatic Model Assessment for insulin-resistance cut-offs that accommodated pubertal and gender differences.
Number of subjects: 153
Study 33239899 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric, metabolic, intake-related variables, and 55 single nucleotide polymorphisms related to NAFLD and choline metabolism were evaluated.
Number of subjects: 153
Study 33240077 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensory prosthesis (Walkasins)
Number of subjects: 45
Study 33240091 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug repurposing for COVID-19
Number of subjects: 16000000
Study 33240091 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing drugs proposed for repurposing
Number of subjects: 16000000
Study 33240091 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory and pharmacological aspects of drug repurposing
Number of subjects: 16000000
Study 33240101 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented oscillations in QT variability (QTV)
Number of subjects: 895
Study 33240121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS) as an add-on treatment to Cognitive-Behavior Therapy (CBT)
Number of subjects: 0
Study 33240125 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical-exercise program
Number of subjects: 0
Study 33240196 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining Compensatory Cognitive Training and Vocational Intervention
Number of subjects: 0
Study 33240196 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 0
Study 33240205 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-extremity rehabilitation using smart glove
Number of subjects: 0
Study 33240205 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33240257 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Equine Encephalitis Vaccine (WEEV; WEE TSI-GSD 210)
Number of subjects: 876
Study 33240282 — intervention group
Group type: EXPERIMENTAL
Intervention: IO103 vaccine with Montanide ISA 51 adjuvant, administered subcutaneously up to fifteen times during 1 year.
Number of subjects: 10
Study 33240315 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min extra counseling about prenatal screening and diagnosis
Number of subjects: 150
Study 33240315 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extra counseling)
Number of subjects: 150
Study 33240399 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan combined with oxaliplatin and S-1
Number of subjects: 41
Study 33240830 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33240920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study 33240920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33240993 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-placed titanium clips
Number of subjects: 55
Study 33240993 — intervention group
Group type: COMPARATOR
Intervention: Conventional GTVs
Number of subjects: 55
Study 33241512 — intervention group
Group type: EXPERIMENTAL
Intervention: Brock model 2b
Number of subjects: 4578
Study 33241512 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-RADS
Number of subjects: 4578
Study 33241512 — intervention group
Group type: EXPERIMENTAL
Intervention: Brock model 2a
Number of subjects: 4578
Study 33242013 — intervention group
Group type: EXPERIMENTAL
Intervention: Soldiers (military population)
Number of subjects: 566
Study 33242013 — intervention group
Group type: COMPARATOR
Intervention: Civilians (control group)
Number of subjects: 566
Study 33242013 — intervention group
Group type: EXPERIMENTAL
Intervention: Officers (military subgroup)
Number of subjects: 566
Study 33242013 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncommissioned Officers (NCOs) (military subgroup)
Number of subjects: 566
Study 33242065 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR2 antibody (MEDI0618)
Number of subjects: 0
Study 33242065 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ8838 and AZ3451 (non-peptide small molecule antagonists)
Number of subjects: 0
Study 33242065 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR2 antibody (Fab3949)
Number of subjects: 0
Study 33242065 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ8838
Number of subjects: 0
Study 33242441 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 0
Study 33242441 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation
Number of subjects: 0
Study 33242457 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine dosed at 6 mg/kg twice daily for term neonates or 4 mg/kg twice daily for 1 week and 6 mg/kg twice daily thereafter for preterm neonates.
Number of subjects: 438
Study 33242457 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine treatment
Number of subjects: 438
Study 33242536 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib for up to 10 weeks before chemotherapy
Number of subjects: 32
Study 33242536 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 32
Study 33242544 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD, DMDD, both disorders, or no major psychopathology
Number of subjects: 187
Study 33242662 — intervention group
Group type: EXPERIMENTAL
Intervention: PD patients
Number of subjects: 24
Study 33242662 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 33242991 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic headache
Number of subjects: 1094